<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066807</url>
  </required_header>
  <id_info>
    <org_study_id>IBCSG 26-02 / BIG 4-02</org_study_id>
    <secondary_id>NABCI-IBCSG-26-02</secondary_id>
    <secondary_id>EU-20401</secondary_id>
    <secondary_id>2005-002626-59</secondary_id>
    <secondary_id>CDR0000318832</secondary_id>
    <nct_id>NCT00066807</nct_id>
  </id_info>
  <brief_title>Premenopausal Endocrine Responsive Chemotherapy Trial</brief_title>
  <acronym>PERCHE</acronym>
  <official_title>A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women With Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Breast International Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Breast Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PERCHE trial evaluated the worth of adding adjuvant chemotherapy for premenopausal women
      with steroid hormone receptor positive early invasive breast cancer who receive ovarian
      function suppression plus either tamoxifen or exemestane for five years. The use of
      chemotherapy was determined by randomization. The method of ovarian function suppression
      (GnRH analogue for five years, surgical oophorectomy or ovarian irradiation) and the choice
      of tamoxifen or exemestane were determined by the investigator or by randomization in the
      IBCSG 25-02 TEXT trial [recommended option]. The trial was terminated early due to poor
      accrual.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare ovarian function suppression and tamoxifen or exemestane with vs without
           adjuvant chemotherapy in premenopausal women with endocrine-responsive resected breast
           cancer.

        -  Compare the disease-free and overall survival of patients treated with these regimens.

        -  Compare sites of first treatment failure in patients treated with these regimens.

        -  Compare the incidence of second nonbreast malignancies in patients treated with these
           regimens.

        -  Compare the quality of life, including late side effects of early menopause, of patients
           treated with these regimens.

      PLANNED OUTLINE:

      This is a randomized, multicenter study. Patients are stratified according to participating
      center, number of positive axillary and/or internal mammary lymph nodes (0 vs 1 or more),
      method of ovarian function suppression (triptorelin vs oophorectomy vs ovarian irradiation),
      chemotherapy if randomized to arm II (not containing vs containing an anthracycline or
      taxane), and endocrine agent (tamoxifen vs exemestane vs selected by subsequent randomization
      in the TEXT trial). Treatment duration is five years.

      Quality of life is assessed at baseline, every 6 months for 2 years, and then annually for 4
      years. Patients are followed every 3 months for 1 year, every 6 months for 5 years, and then
      annually thereafter.

      NOTE: Trial was terminated early due to poor accrual.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual, patients were followed until completion of 5 yrs treatment
  </why_stopped>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>For first time at a median follow up approximately 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>For first time at a median follow up approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Disease-free Survival</measure>
    <time_frame>For first time at a median follow up approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sites of First Treatment Failure</measure>
    <time_frame>For first time at a median follow up approximately 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>OFS plus T or E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy plus OFS plus T or E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy plus ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>Planned duration of chemotherapy: 2 months if an anthracycline is included (e.g., 4 cycles of EC or AC) or 4 months if no anthracycline is given (e.g., 6 cycles of CMF) is recommended. Unless medically contraindicated, an anthracycline-containing regimen using epirubicin should be given.</description>
    <arm_group_label>Chemotherapy plus OFS plus T or E</arm_group_label>
    <other_name>Ellence</other_name>
    <other_name>Epirubicin Ebewe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
    <description>Exemestane 25 mg orally daily for until 5 years from date of randomization, unless relapse or intolerance should occur earlier.</description>
    <arm_group_label>OFS plus T or E</arm_group_label>
    <arm_group_label>Chemotherapy plus OFS plus T or E</arm_group_label>
    <other_name>Aromasin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen</intervention_name>
    <description>Tamoxifen 20 mg orally daily until 5 years from date of randomization, unless relapse or intolerance should occur earlier.</description>
    <arm_group_label>OFS plus T or E</arm_group_label>
    <arm_group_label>Chemotherapy plus OFS plus T or E</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triptorelin</intervention_name>
    <description>Triptorelin (GnRH analogue) 3.75 mg by intramuscular injection every 28 days for 5 years from randomization, unless relapse or intolerance should occur earlier or surgical oophorectomy or ovarian irradiation is subsequently performed.</description>
    <arm_group_label>OFS plus T or E</arm_group_label>
    <arm_group_label>Chemotherapy plus OFS plus T or E</arm_group_label>
    <other_name>GnRH analog</other_name>
    <other_name>Trelstar Depot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>oophorectomy</intervention_name>
    <description>Bilateral surgical oophorectomy via laparotomy or laparoscopy.</description>
    <arm_group_label>OFS plus T or E</arm_group_label>
    <arm_group_label>Chemotherapy plus OFS plus T or E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ovarian irradiation</intervention_name>
    <description>Bilateral ovarian irradiation.</description>
    <arm_group_label>OFS plus T or E</arm_group_label>
    <arm_group_label>Chemotherapy plus OFS plus T or E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed breast cancer confined to the breast and axillary nodes

               -  No distant metastatic disease

               -  Tumor detected in the internal mammary chain by sentinel node procedure allowed

          -  Must have undergone 1 of the following procedures for primary breast cancer within the
             past 12 weeks and have no known clinical residual locoregional disease:

               -  Total mastectomy with or without adjuvant radiotherapy

               -  Breast-conserving surgery (e.g., lumpectomy, quadrantectomy, or partial
                  mastectomy with margins clear* of invasive cancer and ductal carcinoma in situ)
                  followed by radiotherapy NOTE: *If all other margins are clear, a positive
                  posterior (deep) margin is permitted, provided the excision was performed down to
                  the pectoral fascia and all tumor has been removed OR a positive anterior
                  (superficial; abutting skin) margin is allowed provided all tumor was removed

          -  Prior axillary lymph node dissection or negative axillary sentinel node biopsy
             required

               -  Patients with microscopically positive axillary sentinel nodes allowed provided
                  they were evaluated on a clinical trial evaluating microscopically positive lymph
                  nodes

          -  No locally advanced, inoperable breast cancer, including any of the following
             characteristics:

               -  Inflammatory breast cancer

               -  Supraclavicular node involvement

               -  Enlarged internal mammary nodes (unless pathologically negative)

          -  No prior ipsilateral or contralateral invasive breast cancer

               -  Histologically diagnosed synchronous bilateral invasive breast cancer within the
                  past 2 months allowed if the bilateral disease meets all other eligibility
                  criteria

          -  Hormone receptor status:

               -  Estrogen receptor and/or progesterone receptor positive in each tumor

                    -  At least 10% of tumor cells positive by immunohistochemistry

        PATIENT CHARACTERISTICS:

        Age

          -  Premenopausal

        Sex

          -  Female

        Menopausal status

          -  Premenopausal

               -  Estradiol in the premenopausal range after surgery

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  No systemic hepatic disease that would preclude prolonged follow-up

        Renal

          -  No systemic renal disease that would preclude prolonged follow-up

        Cardiovascular

          -  No prior deep venous thrombosis and/or embolism unless patient is medically suitable

          -  No systemic cardiovascular disease that would preclude prolonged follow-up

        Pulmonary

          -  No systemic pulmonary disease that would preclude prolonged follow-up

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective nonhormonal contraception

          -  No other prior or concurrent invasive malignancy except adequately treated basal cell
             or squamous cell skin cancer, nonbreast carcinoma in situ without invasion,
             contralateral or ipsilateral carcinoma in situ of the breast

          -  No prior or concurrent nonbreast invasive malignancy within the past 5 years that is
             nonrecurrent including any of the following:

               -  Stage I papillary thyroid cancer

               -  Stage Ia carcinoma of the cervix

               -  Stage Ia or b endometrioid endometrial cancer

               -  Borderline or stage I ovarian cancer

          -  No other nonmalignant systemic disease that would preclude prolonged follow-up

          -  No history of noncompliance with medical regimens

          -  No psychiatric, addictive, or other disorder that would preclude study compliance or
             giving informed consent

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior neoadjuvant or adjuvant chemotherapy

               -  Neoadjuvant or adjuvant trastuzumab (HerceptinÂ®) allowed

        Endocrine therapy

          -  No prior neoadjuvant or adjuvant endocrine therapy after breast cancer diagnosis

          -  No prior tamoxifen or other selective estrogen-receptor modulator (e.g., raloxifene)
             within 1 year before the breast cancer diagnosis

          -  No other concurrent oral or transdermal hormonal therapy, including any of the
             following:

               -  Estrogen

               -  Progesterone

               -  Androgens

               -  Aromatase inhibitors

               -  Hormone replacement therapy

               -  Oral or other hormonal contraceptives, including implant and depot injections

               -  Raloxifene or other selective estrogen-receptor modulators

        Radiotherapy

          -  See Disease Characteristics

          -  No prior ovarian irradiation

        Surgery

          -  See Disease Characteristics

          -  No prior bilateral oophorectomy

        Other

          -  No other prior neoadjuvant therapy

          -  No other concurrent investigational agents

          -  No concurrent bisphosphonates unless bone density has been documented at least 1.5
             standard deviations below the young adult normal mean or the patient is participating
             in a randomized clinical trial setting testing bisphosphonates in the adjuvant breast
             cancer setting
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosalba Torrisi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Breast International Group, European Institute of Oncology, Milano, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edith A. Perez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>North American Intergroup, Mayo Clinic Jacksonville, Jacksonville, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Aviano</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Francis P, Fleming G, Nasi ML, et al.: Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PGR+) breast cancer: the SOFT, TEXT, and PERCHE trials. [Abstract] The Breast 12 (Suppl 1): A-P104, S44, 2003.</citation>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <results_first_submitted>March 11, 2016</results_first_submitted>
  <results_first_submitted_qc>March 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 11, 2016</results_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment opened 4Aug03; the first patient was randomized on 1Jun04. The accrual goal for the study was 1750 patients. A total of 29 patients were randomized as of 31Dec06 when the trial was terminated. 25 of these 29 patients were also enrolled in the TEXT trial (IBCSG 25-02).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>OFS Plus T or E for 5 Years</title>
          <description>Ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.</description>
        </group>
        <group group_id="P2">
          <title>Chemotherapy Plus OFS Plus T or E for 5 Years</title>
          <description>Chemotherapy plus ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study was terminated early</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OFS Plus T or E for 5 Years</title>
          <description>Ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.</description>
        </group>
        <group group_id="B2">
          <title>Chemotherapy Plus OFS Plus T or E for 5 Years</title>
          <description>Chemotherapy plus ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="42" upper_limit="48"/>
                    <measurement group_id="B2" value="45" lower_limit="42" upper_limit="48"/>
                    <measurement group_id="B3" value="45" lower_limit="42" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival</title>
        <time_frame>For first time at a median follow up approximately 5 years</time_frame>
        <population>The trial was terminated early due to poor accrual. No outcome measure data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>OFS Plus T or E for 5 Years</title>
            <description>Ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy Plus OFS Plus T or E for 5 Years</title>
            <description>Chemotherapy plus ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <population>The trial was terminated early due to poor accrual. No outcome measure data is available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>For first time at a median follow up approximately 5 years</time_frame>
        <population>The trial was terminated early due to poor accrual. No outcome measure data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>OFS Plus T or E for 5 Years</title>
            <description>Ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy Plus OFS Plus T or E for 5 Years</title>
            <description>Chemotherapy plus ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>The trial was terminated early due to poor accrual. No outcome measure data is available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Disease-free Survival</title>
        <time_frame>For first time at a median follow up approximately 5 years</time_frame>
        <population>The trial was terminated early due to poor accrual. No outcome measure data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>OFS Plus T or E for 5 Years</title>
            <description>Ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy Plus OFS Plus T or E for 5 Years</title>
            <description>Chemotherapy plus ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Disease-free Survival</title>
          <population>The trial was terminated early due to poor accrual. No outcome measure data is available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sites of First Treatment Failure</title>
        <time_frame>For first time at a median follow up approximately 5 years</time_frame>
        <population>The trial was terminated early due to poor accrual. No outcome measure data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>OFS Plus T or E for 5 Years</title>
            <description>Ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.</description>
          </group>
          <group group_id="O2">
            <title>Chemotherapy Plus OFS Plus T or E for 5 Years</title>
            <description>Chemotherapy plus ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Sites of First Treatment Failure</title>
          <population>The trial was terminated early due to poor accrual. No outcome measure data is available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5-year protocol treatment period</time_frame>
      <desc>CAVEAT: Trial was terminated early; data available ONLY for selected Grade 3-5 adverse events for chemotherapy arm. Systematic assessment included form with specific AEs related to chemotherapy. 25 out of 29 patients were co-enrolled in TEXT (IBCSG 25-02) and AEs associated with endocrine therapy are reported as part of that trial.</desc>
      <group_list>
        <group group_id="E1">
          <title>OFS Plus T or E for 5 Years</title>
          <description>Ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.</description>
        </group>
        <group group_id="E2">
          <title>Chemotherapy Plus OFS Plus T or E for 5 Years</title>
          <description>Chemotherapy plus ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Trial terminated early due to poor accrual. Adverse event data is available ONLY for selected Grade 3-5 AEs for chemotherapy arm. 25 of 29 patients were co-enrolled in TEXT (IBCSG 25-02), which reports AEs and outcomes of endocrine therapy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Rudolf Maibach, Executive Officer for International Trial Activities</name_or_title>
      <organization>IBCSG</organization>
      <phone>+41 31 389 91 96</phone>
      <email>rudolf.maibach@ibcsg.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

